Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
2008 ◽
Vol 26
(15_suppl)
◽
pp. 1089-1089
◽
Keyword(s):
Phase Ii
◽